Pfizer to seek emergency approval for COVID vaccine next month

Russia Approves 2nd Coronavirus Vaccine – Putin

After Sputnik V, Russia Approves 2nd COVID-19 Vaccine EpiVacCorona; Putin Says 3rd One Almost Ready

The first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore received an injection in May. An initial readout on whether the vaccine is effective could come later this month, depending on how quickly subjects in the trial - some of whom got a placebo shot - become infected with the virus.

The CDC has said that if supplies are limited, the earliest inoculations may go to healthcare workers, people at increased risk for severe COVID-19, people aged 65 years and older and essential workers. In areas with large outbreaks and community spread, infections will pile up faster.

"When the vaccines are approved, we will produce them in Venezuela and we will vaccinate the entire population against the coronavirus", the president said.

The United States, the European Union, the United Kingdom and the World Health Organization have all set similar minimum standards for effectiveness. So far, 44,000 people have taken part in clinical trials for the vaccine worldwide, including President Rodrigo Duterte of the Philippines, who was inoculated in May this year.

"Moderna could also apply for an emergency use authorization (EUA) this year".

Twitter briefly restricts Trump campaign account
It also claimed Joe Biden had met with one of the company's advisers. But the newspaper's source for the information raised questions.

"We need to increase production of our first and now our second vaccine, first of all we should supply the domestic market", Mr Putin said, adding that Russian Federation will also work with foreign partners to make the inoculations. Every pharmacy will also be staffed with a nurse as government regulations stipulate that only doctors and nurses can administer a vaccine injection.

The U.S. Food and Drug Administration has said it will not approve a vaccine unless it is both effective and safe. Another U.S. trial of a candidate from Johnson & Johnson JNJ.N was paused earlier this week.

The Food and Drug Administration (FDA), which authorizes pharmaceuticals for distribution in the USA - asked vaccine developers last week to spend two months monitoring for serious side effects after the second dose is given to trial participants. The agency will consider an emergency use authorization (EUA) once that data is collected from at least half of the trial's participants.

Russian Federation has approved a second coronavirus vaccine for use, despite the jab not undergoing mass testing.

Regulators will review the vaccines after the companies have enough data to submit applications seeking an EUA or formal approval. AstraZeneca could provide a look at late-stage data in November. It has said that it may have interim data on its 30,000 person trial as soon as November.

Alabama Crimson Tide head coach Nick Saban tests positive for COVID-19
When and how that changes upon Saban's contraction of COVID-19 remains to be seen. "I immediately left work and isolated at home. Sarkisian previously served as the Washington Huskies and USC Trojans head coach.

This is the first time any "leading Western vaccine developer provided such a specific timeline", according to the Wall Street Journal.

Yes, although China and Russian Federation are on a similar timeline.

Early trials on 100 volunteers were said to have been successful.

Pfizer Inc. said it could seek emergency-use authorization for its Covid-19 vaccine in the late November if the shot is shown to be effective in a large late-stage trial, putting to rest any notion that a vaccine could be cleared for emergency use in the USA before Election Day.

Le groupe, sans Neymar — Nîmes-PSG
Le coach allemand qui s'est ensuite montré pessimiste au moment d'évoquer Leandro Paredes . " Leandro j'ai des doutes". Autour de lui on aura noté les prouesses techniques de Mbappé et les montées de Florenzi et Mitchel Bakker.

Latest News